botensilimab,balstilimab
agenus
botensilimab was well tolerated, with no grade 4 or 5 treatment-related adverse events. no hypophysitis and pneumonitis is rare. #esmogi
Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants